 |
97 Diseases |  |
247 Trials |
|
247 Trials |  |
14602 News |  |
| «12...154155156157158159160161162163164...170171» |
- | rivaroxaban / Generic mfg., apixaban / Generic mfg.
Clinical, Journal: Importance of balancing follow-up time and impact of oral-anticoagulant users' selection when evaluating medication adherence in atrial fibrillation patients treated with rivaroxaban and apixaban. (Pubmed Central) - Jan 5, 2018
Medication adherence comparisons need to account for differences in follow-up. Selection of chronic medication users may impact comparative adherence advantage between medications.
- | Preclinical, Journal: A single test to assay warfarin, dabigatran, rivaroxaban, apixaban, unfractionated heparin and enoxaparin in plasma. (Pubmed Central) - Jan 4, 2018
Dabigatran, rivaroxaban, and apixaban could be accurately measured in patient samples using both dilute PT assays, but a better correlation was consistently observed between the dFiix-PT and specific assays than with the dPT. Conclusion The dFiix-PT using a single dilution of TP may be suitable to assess the anticoagulant effects of warfarin, dabigatran, rivaroxaban, apixaban, heparin, and enoxaparin.
- | rivaroxaban / Generic mfg.
Clinical, Journal: Overall Effectiveness of Rivaroxaban in Patients with Pulmonary Embolism. (Pubmed Central) - Dec 27, 2017
Conclusion The dFiix-PT using a single dilution of TP may be suitable to assess the anticoagulant effects of warfarin, dabigatran, rivaroxaban, apixaban, heparin, and enoxaparin. Patients with PE prescribed rivaroxaban had similar PE-related outcomes, but fewer HACs and lesser total costs, than did patients on SOC.
- || Xarelto (rivaroxaban) / J&J
Trial suspension: RASET: Rivaroxaban Anticoagulation for Superficial Vein Thrombosis (clinicaltrials.gov) - Dec 20, 2017
P3, N=600, Suspended, Sponsor: McMaster University
Patients with PE prescribed rivaroxaban had similar PE-related outcomes, but fewer HACs and lesser total costs, than did patients on SOC. Recruiting --> Suspended
- | Retrospective data, Journal: Safety of Endovascular Intervention for Stroke on Therapeutic Anticoagulation: Multicenter Cohort Study and Meta-Analysis. (Pubmed Central) - Dec 16, 2017
Recruiting --> Suspended Endovascular intervention in subjects on therapeutic anticoagulation appears reasonably safe, with a sICH rate similar to patients not on anticoagulation receiving IV tPA.
- ||| rivaroxaban / Generic mfg., warfarin / Generic mfg.
New trial, HEOR: Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients (clinicaltrials.gov) - Dec 14, 2017
P=N/A, N=99999, Recruiting, Sponsor: Bayer
- | rivaroxaban / Generic mfg.
Enrollment open, Phase classification, Trial initiation date: Absorption of Rivaroxaban in Patients With Cervical Spinal Cord Injury (clinicaltrials.gov) - Dec 14, 2017
P4, N=24, Recruiting, Sponsor: Swiss Paraplegic Centre Nottwil
Endovascular intervention in subjects on therapeutic anticoagulation appears reasonably safe, with a sICH rate similar to patients not on anticoagulation receiving IV tPA. Not yet recruiting --> Recruiting | Phase classification: PN/A --> P4 | Initiation date: Jan 2017 --> Dec 2017
- ||| Praxbind (idarucizumab) / Boehringer Ingelheim
Trial completion, Surgery, Claims database: Medical Need of OAC Reversal (clinicaltrials.gov) - Dec 11, 2017
P=N/A, N=12000, Completed, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting | Phase classification: PN/A --> P4 | Initiation date: Jan 2017 --> Dec 2017 Recruiting --> Completed
- ||| Praxbind (idarucizumab) / Boehringer Ingelheim
Enrollment open, Surgery, Claims database: Medical Need of OAC Reversal (clinicaltrials.gov) - Dec 8, 2017
P=N/A, N=12000, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Completed Not yet recruiting --> Recruiting
- | rivaroxaban / Generic mfg.
Journal: Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. (Pubmed Central) - Dec 5, 2017
P3
The primary efficacy hypothesis is that anticoagulation with rivaroxaban reduces the composite of objectively confirmed symptomatic or asymptomatic, lower-extremity, proximal deep-vein thrombosis (DVT); symptomatic, upper-extremity DVT; symptomatic or incidental pulmonary embolism; and VTE-related death compared with placebo. The primary safety objective is to assess major bleeding events (Clinical trial information: NCT02555878).
- | rivaroxaban / Generic mfg.
New P4 trial: H-REPLACE: Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome (clinicaltrials.gov) - Dec 5, 2017
P4, N=3390, Not yet recruiting, Sponsor: Second Xiangya Hospital of Central South University
- ||| rivaroxaban / Generic mfg., warfarin / Generic mfg.
New trial: CALLIPER: Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction (clinicaltrials.gov) - Dec 2, 2017
P=N/A, N=11000, Not yet recruiting, Sponsor: Bayer
- | Journal: Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis. (Pubmed Central) - Nov 30, 2017
The primary safety objective is to assess major bleeding events (Clinical trial information: NCT02555878). With the possible exception of apixaban, newer anticoagulants that lower the risk of postoperative VTE increase bleeding.
- ||| rivaroxaban / Generic mfg.
Enrollment change: Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification (clinicaltrials.gov) - Nov 30, 2017
P4, N=190, Recruiting, Sponsor: RWTH Aachen University
With the possible exception of apixaban, newer anticoagulants that lower the risk of postoperative VTE increase bleeding. N=253 --> 190
- | Enrollment open, Trial primary completion date: Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 80 Years and Over (clinicaltrials.gov) - Nov 27, 2017
P=N/A, N=2193, Recruiting, Sponsor: Assistance Publique - H
N=253 --> 190 Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2019 --> Apr 2018
- ||| rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
Trial completion, Enrollment change: Use of Direct Oral Anticoagulants in UK (clinicaltrials.gov) - Nov 21, 2017
P=N/A, N=31336, Completed, Sponsor: Bayer
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2019 --> Apr 2018 Active, not recruiting --> Completed | N=3000 --> 31336
- | rivaroxaban / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: CATHAR: Comparison of Antithrombotic Treatments After Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve. (clinicaltrials.gov) - Nov 17, 2017
P2, N=12, Terminated, Sponsor: University Hospital Inselspital, Berne
Active, not recruiting --> Completed | N=3000 --> 31336 N=30 --> 12 | Suspended --> Terminated | Trial primary completion date: Jan 2018 --> Sep 2017; not enough patients
- Ciraparantag (aripazine) / Norgine, Covis Pharma
Trial primary completion date: Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT (clinicaltrials.gov) - Nov 17, 2017
P2, N=48, Recruiting, Sponsor: Perosphere, Inc.
N=30 --> 12 | Suspended --> Terminated | Trial primary completion date: Jan 2018 --> Sep 2017; not enough patients Trial primary completion date: Oct 2017 --> Jan 2018
- || rivaroxaban / Generic mfg.
Trial primary completion date: Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children (clinicaltrials.gov) - Nov 7, 2017
P1, N=58, Recruiting, Sponsor: Bayer
Trial primary completion date: Oct 2017 --> Jan 2018 Trial primary completion date: Dec 2017 --> Mar 2018
- ||| AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Trial completion: A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa (clinicaltrials.gov) - Nov 6, 2017
P1, N=153, Completed, Sponsor: Portola Pharmaceuticals
Trial primary completion date: Dec 2017 --> Mar 2018 Active, not recruiting --> Completed
- | rivaroxaban / Generic mfg.
Trial primary completion date: RIPORT: Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis. (clinicaltrials.gov) - Nov 6, 2017
P3, N=296, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Active, not recruiting --> Completed Trial primary completion date: Sep 2019 --> Sep 2020
- | rivaroxaban / Generic mfg., ticagrelor / Generic mfg.
New P3 trial: CAPITALPCIAF: The Safety and Efficacy Of Rivaroxaban and Ticagrelor for Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (clinicaltrials.gov) - Nov 6, 2017
P3, N=190, Not yet recruiting, Sponsor: Ottawa Heart Institute Research Corporation
- | rivaroxaban / Generic mfg.
Journal: Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). (Pubmed Central) - Nov 4, 2017
Of the 9 patients in the warfarin group, there was 1 nonfatal bleeding event and 3 deaths, most occurring when thrombolytic therapy was administered outside of 48 hours from the last warfarin dose. In conclusion, these observations suggest that careful assessment of the time since the last dose may be of clinical significance in patients on novel oral anticoagulants who require emergent thrombolysis.
- | tranexamic acid IV / Generic mfg.
New P4 trial: Combined Topical Tranexamic Acid With Floseal® in Total Knee Arthroplasty (clinicaltrials.gov) - Nov 1, 2017
P4, N=70, Not yet recruiting, Sponsor: Chang Gung Memorial Hospital
- | Review, Journal: Anticoagulation in Pulmonary Embolism: Update in the Age of Direct Oral Anticoagulants. (Pubmed Central) - Nov 1, 2017
Currently, dabigatran, rivaroxaban, apixiban, and edoxoban are approved and used routinely for the prevention and treatment of patients with venous thromboembolism...This article focuses on the practical considerations of how and when to use the DOACs. It also aims to explore follow-up monitoring, use in special populations, reversal agents, periprocedural management, and how to handle bleeding complications with the DOACs.
- | rivaroxaban / Generic mfg.
Trial primary completion date: The Effect of Rivaroxaban in Sickle Cell Disease (clinicaltrials.gov) - Oct 31, 2017
P2, N=34, Enrolling by invitation, Sponsor: University of North Carolina, Chapel Hill
It also aims to explore follow-up monitoring, use in special populations, reversal agents, periprocedural management, and how to handle bleeding complications with the DOACs. Trial primary completion date: Dec 2017 --> May 2018
- |||| rivaroxaban / Generic mfg.
Trial primary completion date: EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis (clinicaltrials.gov) - Oct 27, 2017
P3, N=270, Recruiting, Sponsor: Bayer
Trial primary completion date: Dec 2017 --> May 2018 Trial primary completion date: Jul 2019 --> Jul 2018
- | Savaysa (edoxaban) / Daiichi Sankyo
Trial initiation date: Start or STop Anticoagulants Randomised Trial (SoSTART) (clinicaltrials.gov) - Oct 27, 2017
P3, N=800, Not yet recruiting, Sponsor: University of Edinburgh
Trial primary completion date: Jul 2019 --> Jul 2018 Initiation date: Jul 2017 --> Feb 2018
- | Xarelto (rivaroxaban) / J&J
Trial initiation date: SECRET: Study of Rivaroxaban for CeREbral Venous Thrombosis (clinicaltrials.gov) - Oct 27, 2017
P2, N=384, Not yet recruiting, Sponsor: University of British Columbia
Initiation date: Jul 2017 --> Feb 2018 Initiation date: Jun 2017 --> Jan 2018
- | Bayer Advanced Aspirin (aspirin fast release) / Bayer
Trial termination, Head-to-Head: NAVIGATE ESUS: Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS) (clinicaltrials.gov) - Oct 23, 2017
P3, N=6934, Terminated, Sponsor: Bayer
Initiation date: Jun 2017 --> Jan 2018 Recruiting --> Terminated; Study halted early due to no efficacy improvement over aspirin at an interim analysis and very little chance of showing overall benefit if study were completed
- | Review, Journal: Management of bleeding in patients receiving non-vitamin K antagonists. (Pubmed Central) - Oct 22, 2017
Andexanet alfa reduces increased anti-factor Xa activity seen with the use of rivaroxaban and apixaban...The development of reversal agents is a major advancement in managing bleeding in the era of NOACs. Future studies will be required to determine the impact on important clinical outcomes.
- ||| rivaroxaban / Generic mfg.
New trial: RIVA-PCI: Rivaroxaban in Patients With Atrial Fibrillation Undergoing PCI (clinicaltrials.gov) - Oct 20, 2017
P=N/A, N=2100, Not yet recruiting, Sponsor: IHF GmbH - Institut für Herzinfarktforschung
- |||| Xarelto (rivaroxaban) / J&J
Trial completion, Enrollment change, Trial primary completion date: RAPS: Rivaroxaban for Antiphospholipid Antibody Syndrome (clinicaltrials.gov) - Oct 18, 2017
P4, N=81, Completed, Sponsor: St. Joseph's Healthcare Hamilton
Future studies will be required to determine the impact on important clinical outcomes. Recruiting --> Completed | N=150 --> 81 | Trial primary completion date: Dec 2016 --> Sep 2017
- ||| rivaroxaban / Generic mfg.
Enrollment open: XaMINA: Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment-naïve Asian Patients With Non-valvular Atrial Fibrillation (clinicaltrials.gov) - Oct 16, 2017
P=N/A, N=1200, Recruiting, Sponsor: Bayer
Recruiting --> Completed | N=150 --> 81 | Trial primary completion date: Dec 2016 --> Sep 2017 Not yet recruiting --> Recruiting
- | Xarelto (rivaroxaban) / J&J
Trial primary completion date: Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis (clinicaltrials.gov) - Oct 13, 2017
P3, N=40, Recruiting, Sponsor: Sherief Abd-Elsalam
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2017 --> Jul 2020
- || rivaroxaban / Generic mfg.
Enrollment closed: X-PRESS: Xarelto Evidence in Real Life of Patients' Preference and Satisfaction Study (clinicaltrials.gov) - Oct 12, 2017
P=N/A, N=255, Active, not recruiting, Sponsor: Bayer
Trial primary completion date: Jul 2017 --> Jul 2020 Recruiting --> Active, not recruiting
- | Savaysa (edoxaban) / Daiichi Sankyo
Enrollment open: Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial (clinicaltrials.gov) - Oct 12, 2017
P=N/A, N=2000, Recruiting, Sponsor: University Hospital Inselspital, Berne
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | rivaroxaban / Generic mfg.
Journal: Outcomes associated with observation status versus inpatient management of pulmonary embolism patients anticoagulated with rivaroxaban. (Pubmed Central) - Oct 5, 2017
Not yet recruiting --> Recruiting No abstract available
- | rivaroxaban / Generic mfg., enoxaparin sodium / Generic mfg.
New P3 trial, HEOR, Surgery, Cost effectiveness: Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Comparison Between Rivaroxaban and Enoxaparin (clinicaltrials.gov) - Oct 3, 2017
P3, N=100, Enrolling by invitation, Sponsor: Ahmed AbdelMoneim Hassan Ali
- | Xarelto (rivaroxaban) / J&J
Trial primary completion date: Rivaroxaban for Scheduled Work-up of DVT - The Ri-Schedule Study (clinicaltrials.gov) - Oct 2, 2017
P3, N=825, Recruiting, Sponsor: Ostfold Hospital Trust
No abstract available Trial primary completion date: Aug 2017 --> Dec 2018
- | rivaroxaban / Generic mfg., warfarin / Generic mfg.
Journal: Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial. (Pubmed Central) - Sep 27, 2017
DAPT was used in a variable manner, with the majority of patients remaining on study drug after PCI. Rates of both thrombotic and bleeding events were high after PCI, highlighting the need for studies to determine the optimal antithrombotic therapy.
- ||| rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
Trial completion, Retrospective data, Enrollment change: The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis (clinicaltrials.gov) - Sep 25, 2017
P=N/A, N=35130, Completed, Sponsor: Boehringer Ingelheim
Rates of both thrombotic and bleeding events were high after PCI, highlighting the need for studies to determine the optimal antithrombotic therapy. Recruiting --> Completed | N=47000 --> 35130
- || rivaroxaban / Generic mfg.
Trial primary completion date: Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France (clinicaltrials.gov) - Sep 25, 2017
P=N/A, N=99999, Recruiting, Sponsor: Bayer
Recruiting --> Completed | N=47000 --> 35130 Trial primary completion date: Sep 2017 --> Dec 2017
- | warfarin / Generic mfg.
New trial, Adverse events, HEOR: Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study (clinicaltrials.gov) - Sep 24, 2017
P=N/A, N=19200, Recruiting, Sponsor: University of California, San Francisco
- |||||| rivaroxaban / Generic mfg.
Enrollment open: ADRIFT: Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure (clinicaltrials.gov) - Sep 20, 2017
P2/3, N=90, Recruiting, Sponsor: Assistance Publique - H
Trial primary completion date: Sep 2017 --> Dec 2017 Not yet recruiting --> Recruiting
- || Praxbind (idarucizumab) / Boehringer Ingelheim
Enrollment change, Surgery, Claims database: Medical Need of OAC Reversal (clinicaltrials.gov) - Sep 16, 2017
P=N/A, N=12000, Not yet recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting N=62888 --> 12000
- ||| rivaroxaban / Generic mfg.
New trial: XaMINA: Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment-naïve Asian Patients With Non-valvular Atrial Fibrillation (clinicaltrials.gov) - Sep 15, 2017
P=N/A, N=1200, Not yet recruiting, Sponsor: Bayer
- | Savaysa (edoxaban) / Daiichi Sankyo
Phase classification: PRiSMA-AF: Anticoagulation Preference by AF Patients Study (clinicaltrials.gov) - Sep 14, 2017
P=N/A, N=198, Completed, Sponsor: Bayer
N=62888 --> 12000 Phase classification: P4 --> P=N/A
- | rivaroxaban / Generic mfg.
Journal: Rates of Major Bleeding With Rivaroxaban in Real-World Studies of Nonvalvular Atrial Fibrillation Patients: A Meta-Analysis. (Pubmed Central) - Sep 14, 2017
We performed a meta-analysis to better quantify the rates of different types of major bleeding seen with rivaroxaban in observational studies. The pooled rates of major bleeding with rivaroxaban were generally low and consistent with those reported in its pivotal randomized controlled trial.
- | rivaroxaban / Generic mfg.
New P1/2 trial: Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer Patients (clinicaltrials.gov) - Sep 13, 2017
P1/2, N=300, Recruiting, Sponsor: Capital Medical University